A Phase 2, Multicenter, Open-Label, Single Arm, Two-Stage Study to Evaluate the Efficacy and Safety of CC-4047 (Pomalidomide) in Patients With Advanced Soft Tissue Sarcomas Who Have Relapsed or Are Refractory to Systemic Anticancer Therapy.

Trial Profile

A Phase 2, Multicenter, Open-Label, Single Arm, Two-Stage Study to Evaluate the Efficacy and Safety of CC-4047 (Pomalidomide) in Patients With Advanced Soft Tissue Sarcomas Who Have Relapsed or Are Refractory to Systemic Anticancer Therapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Pomalidomide (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 15 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 12 Aug 2009 Actual patient number (7) added as reported by ClinicalTrials.gov.
    • 12 Aug 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top